Bleakley Financial Group LLC Takes Position in Edwards Lifesciences Corporation $EW

Key Points

• Bleakley Financial Group LLC bought a new stake in Edwards Lifesciences during the fourth quarter, purchasing 39,581 shares valued at about $3.37 million.
• Institutional ownership remains heavy, with hedge funds and other investors holding 79.46% of the company’s stock, while several other firms also recently added to or initiated positions.
• Edwards Lifesciences reported better-than-expected quarterly results, posting $0.78 EPS on $1.65 billion in revenue, and analysts currently rate the stock Moderate Buy with an average target price of $95.65.

Bleakley Financial Group LLC purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 39,581 shares of the medical research company's stock, valued at approximately $3,374,000.

Other institutional investors have also recently made changes to their positions in the company. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $25,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $28,000. Hantz Financial Services Inc. raised its stake in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company's stock valued at $29,000 after purchasing an additional 164 shares during the period. Dorato Capital Management bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $29,000. Finally, Rakuten Securities Inc. raised its stake in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock valued at $29,000 after purchasing an additional 302 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of analyst reports. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a "hold" rating in a research note on Friday, April 24th. The Goldman Sachs Group reiterated a "buy" rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Piper Sandler reiterated an "overweight" rating and set a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Evercore reiterated an "outperform" rating and set a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Finally, Barclays reiterated an "overweight" rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $95.65.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $86.55 on Thursday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $49.83 billion, a PE ratio of 46.04, a price-to-earnings-growth ratio of 2.19 and a beta of 0.87. The business's 50-day moving average price is $81.62 and its 200-day moving average price is $82.97. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $88.28.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company's revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares of the company's stock, valued at $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,829 shares of company stock worth $8,799,770 in the last ninety days. 0.31% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.